COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

CDC Prevention Epicenters Wake Up and Breathe Collaborative

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01583413
Recruitment Status : Completed
First Posted : April 24, 2012
Last Update Posted : October 11, 2013
Centers for Disease Control and Prevention
Washington University School of Medicine
Rush University Medical Center
University of Pennsylvania
Duke University
North Shore Medical Center
Information provided by (Responsible Party):
Michael Klompas MD, MPH, FRCPC, Harvard Pilgrim Health Care

Brief Summary:

Ventilator-associated pneumonia (VAP) is a common complication of mechanical ventilation associated with significant morbidity, including prolongation of mechanical ventilation and increased ICU and hospital length-of-stay. Numerous strategies have been proposed to decrease the occurrence of VAP among ventilated patients. Most notably, optimizing the use of daily sedative interruptions and daily spontaneous breathing trials can improve sedative management, decrease ventilator time, improve outcomes for mechanically ventilated patients,and possibly decrease VAP.Combining daily sedative interruption with daily spontaneous breathing trials confers additive improvement in ventilator days, intensive care days, and possibly mortality compared to daily spontaneous breathing trials alone.

The primary aim of this study is to determine the impact of an opt-out protocol for paired daily sedative interruptions and spontaneous breathing trials on VAP rates using a new streamlined VAP definition. The investigators will evaluate the responsiveness of CDC's proposed new surveillance definitions for ventilator-associated events to this quality improvement initiative. The study will be nested within the Epicenters Streamlined versus Conventional VAP Surveillance Study. Nine of the 18 hospitals in the larger study will be participating in this intervention arm.

Condition or disease Intervention/treatment Phase
Ventilator-associated Pneumonia Procedure: Daily SAT & SBT Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3342 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: CDC Prevention Epicenters Wake Up and Breathe Collaborative
Study Start Date : May 2012
Actual Primary Completion Date : June 2013
Actual Study Completion Date : October 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia

Arm Intervention/treatment
Experimental: Opt Out Protocol Procedure: Daily SAT & SBT
Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.

Primary Outcome Measures :
  1. Change in VAC rate. [ Time Frame: 12 months ]

    A new definition for VAP is the primary focus of this study. This new definition (referred to as "streamlined VAP" or "sVAP") is under consideration by the CDC as a potential replacement for the current NHSN VAP definition and, as such, will be closely evaluated to determine if it can reflect meaningful changes in patient care. Thus, we will assess the change in monthly sVAP rates from study start to study end using an interrupted time series analysis.

    Note that CDC released new surveillance definitions for ventilator-associated events in late 2012. Given that CDC definitions are the defacto surveillance standard, we switched the primary study outcome from sVAP to ventilator-associated conditions ("VAC"). All data elements required to assess for VAC were included in this study from the outset hence we did not have to collect any additional historical data in order to apply CDC's VAC definition.

Secondary Outcome Measures :
  1. ICU-specific outcomes [ Time Frame: 12-months ]
    • NHSN VAP rate
    • Mechanical ventilation days per patient
    • Ventilator-free days assessed over 28 days post-intubation
    • ICU length of stay per patient
    • Average antibiotic days
    • Rates of extubation and reintubation within 48 hours

  2. Hospital-specific outcomes [ Time Frame: 12-months ]
    • Hospital length of stay
    • Hospital mortality

  3. Patient-specific outcomes [ Time Frame: 12-months ]
    • Mean ventilator days
    • Mean ICU days
    • Mean hospital days

    The above results will also be assessed separately for patients who received opt-out protocol care versus those who did not.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • all patients in participating units on mechanical ventilation for at least one calendar day beting treated with continuous sedatives or standing orders for sedatives. Patients receiving mechanical ventilation through either an endotracheal or tracheostomy tube will be eligible.

Exclusion Criteria:

  • moribund status or plans for withdrawal of life support

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01583413

Layout table for location information
United States, Illinois
Chicago Prevention Epicenter
Chicago, Illinois, United States
United States, Massachusetts
North Shore Medical Center
Salem, Massachusetts, United States
United States, Missouri
Washington University Prevention Epicenter
St. Louis, Missouri, United States
United States, North Carolina
Duke University Prevention Epicenter
Durham, North Carolina, United States
United States, Pennsylvania
University of Pennsylvania Prevention Epicenter
Philadelphia, Pennsylvania, United States
Sponsors and Collaborators
Harvard Pilgrim Health Care
Centers for Disease Control and Prevention
Washington University School of Medicine
Rush University Medical Center
University of Pennsylvania
Duke University
North Shore Medical Center
Layout table for investigator information
Principal Investigator: Michael Klompas, MD, MPH Harvard Pilgrim Health Care
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Michael Klompas MD, MPH, FRCPC, Principal Investigator, Harvard Pilgrim Health Care Identifier: NCT01583413    
Other Study ID Numbers: PH000410A-2
3U54CK000172-01S1 ( U.S. NIH Grant/Contract )
First Posted: April 24, 2012    Key Record Dates
Last Update Posted: October 11, 2013
Last Verified: October 2013
Keywords provided by Michael Klompas MD, MPH, FRCPC, Harvard Pilgrim Health Care:
Ventilator-associated pneumonia
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Ventilator-Associated
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Cross Infection